Preventive migraine therapy: What is new

Neurological Sciences

Volumn 25, Issue SUPPL. 3, 2004, Pages

  Rapoport, A M ^a,c   Bigal, M E ^b,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

Headache prevention; Migraine prevention; Migraine treatment

Indexed keywords

AMITRIPTYLINE; ATENOLOL; BOTULINUM TOXIN A; CANDESARTAN; CANDESARTAN HEXETIL; CLONIDINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; GUANFACINE; KETOPROFEN; LISINOPRIL; METOPROLOL; MIRTAZAPINE; NADOLOL; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PETASIN; PETASITES HYBRIDUS EXTRACT; PHENELZINE; PLANT EXTRACT; PROPRANOLOL; SERTRALINE; TIMOLOL; TIZANIDINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; VERAPAMIL; ZONISAMIDE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIOXIDANT; BENZIMIDAZOLE DERIVATIVE; BOTULINUM TOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; FRUCTOSE; NEUROPROTECTIVE AGENT; TETRAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; UBIDECARENONE; UBIQUINONE;

ANHIDROSIS; ANXIETY DISORDER; ASTHENIA; CARCINOGENESIS; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFERENCE PAPER; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHORIA; FATIGUE; HEADACHE; HUMAN; HYPERTHERMIA; HYPOTHERMIA; INFECTION; IRRITABILITY; LIVER INJURY; MIGRAINE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; PARESTHESIA; PROPHYLAXIS; PTOSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; PATHOPHYSIOLOGY; PETASITES; PHYTOTHERAPY; REVIEW;

ANALGESICS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIOXIDANTS; BENZIMIDAZOLES; BOTULINUM TOXINS; CLONIDINE; FRUCTOSE; HUMANS; LISINOPRIL; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PETASITES; PHYTOTHERAPY; TETRAZOLES; TRIAZOLES; UBIQUINONE;

EID: 16544389653     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-004-0281-9     Document Type: Conference Paper

References (51)

1. Scher AI, Stewart WF, Lipton RB (1999) Migraine and headache: a meta-analytic approach. In: Crombie IK (ed) Epidemiology of pain, IASP Press, Seattle, pp 159-170
2. Stewart WF, Shechter A, Lipton RB (1994) Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 44[Suppl 4]:24-39
3. Lipton RB, Hamelsky SW, Stewart WF (2001) Epidemiology and impact of migraine. In: Silberstein SD, Lipton RB, Dalessio DJ (eds) Wolff's headache and other head pain. Oxford University Press, New York, pp 85-107
4. Lipton RB, Stewart WF, Simon D (1998) Medical consultation for migraine: results from the American Migraine Study. Headache 38:87-96
5. Stang PE, Von Korff M (1994) The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 34:138-142.
6. Goadsby PJ (2001) Pathophysiology of headache. In: Silberstein SD, Lipton RB, Dalessio DJ (eds) Wolff's headache and other head pain, 7th Edn. Oxford University Press, Oxford, England, pp 57-72
7. May A, Goadsby PJ (1999) The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 19:115-127. ** Review on the pathophysiology of migraine
8. Weiller C, May A, Limmroth V et al (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658-660
9. Welch KM, Barkley GL, Tepley N et al (1993) Central neurogenic mechanisms of migraine. Neurology 43:S21-S25
10. Van Harreveld A (1984) The nature of chick's magnesium-sensitive retinal spreading depression. J Neurobiol 15:333-344
11. Schaumburg HH, Byck R, Gersti R, Mashman JN (1969) Monosodium L-glutamate: its pharmacology and role in the Chinese restaurant syndrome. Science 163:826-828
12. Ferrari MD, Odink K, Bos KD et al (1990) Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 40:1582-1586
13. Cananzi AR, D'Andrea G, Perini F et al (1995) Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 15:132-135
14. Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P (2003) Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 23:166-174
15. Welch KM, Chabi E, Bartosh K, Achar VS, Meyer JS (1975) Cerebrospinal fluid gamma aminobutyric acid levels in migraine. Br Med J 3:516-517
16. Storer RJ, Akerman S, Goadsby PJ (2001) GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol. 134:896-904
17. Silberstein SD, Goadsby PJ (2002) Migraine: a preventive treatment. Cephalalgia 22:491-512. ** Extensive evidence-based review on current migraine preventive medications.
18. Shank RP et al (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41[Suppl 1]:S3-S9
19. Garnett WR (2000) Clinical pharmacology of topiramate: a review. Epilepsia 41[Suppl 1]:S61-S65
20. Topamax® [package insert] (2002) Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ
21. Shuaib A, Ahmed F, Muratoglu M et al (1999) Topiramate in migraine prophylaxis: a pilot study. (Abstract) Cephalalgia 19:379-380
22. Edwards KR, Glautz MJ, Shea P (2000) Topiramate for migraine prophylaxis: a double-blind, randomized, placebo-controlled study (Abstract). Headache 40:407
23. Potter DL, Hart DE, Calder CS et al (2000) A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. (Abstract) Neurology 54 [Suppl 3]:A15
24. Silberstein SD et al (2002) Poster presented at: Migraine Trust International Symposium; September 2002, London, UK
25. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D; MIGR-002 Study Group (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965-973 ** One of the largest preventive clinical trials to date.
26. Jones MW (1998) Topiramate - safety and tolerability. Can J Neurol Sci 25:13-15
27. Krusz JC (2001) Levetiracetam as prophylaxis for resistant headaches. (Abstract) Cephalalgia 21:373
28. Drake ME, Greathouse NI, Armentbright AD, Renner JB (2001) Levetiracetam for preventive treatment of migraine. (Abstract) Cephalalgia 21:373
29. Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME (2004) Levetiracetam in the preventive treatment of transformed migraine (Abstract). Headache (in press).
30. Drake ME, Greathouse NI, Armentbright AD, Renner JB (2001) Preventive treatment of migraine with zonisamide. (Abstract). Cephalalgia 21:374
31. Krusz JC (2001) Zonisamide in the treatment of headache disorders. (Abstract). Cephalalgia 21:374-375
32. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM (2000) Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123:669-676
33. Zwart JA, Bovim G, Sand T, Sjaastad O (1994) Tension headache: botulinum toxin paralysis of temporal muscles. Headache 34:458-462
34. Relja MA (1997) Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 4[Suppl 2]:71-72
35. Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy headache. J Head Face Pain 44:35-43. * This paper investigates the mechanism of action of botulinum toxin in migraine
36. Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40:445-450. *Double blind, placebo controlled trial assessing the efficacy of botulinum toxin in the treatment of migraine
37. Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM (2004) Botulin toxin type a in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache (in press).
38. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A (2003) Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 43:884-891
39. Saper JR, Winner PK, Lake AE (2001) An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache 41:357-368
40. Lake AE, Saper JR, Spiering EL, Cantrell DT, Winner PK, White J (2002) Chronic daily headache prophylaxis with tizanidine: a double-blind, multicenter outcome study. (Abstract). Headache 42:430
41. Saper JR, Lake AE, Tepper SJ (2001) Nefazadone for chronic daily headache prophylaxis: an open-label study. Headache 111:465-474
42. Skidgel RA, Erdos EG (1987) The broad substrate specificity of human angiotensin converting enzyme. Clin Exp Hypertens A 9:243-259
43. Paterna S, DiPasquale P, D'Angelo A et al (2000) Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 43:133-136
44. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65-69
45. Eaton J (1998) Butterbur, herbal help for migraine. Natural Pharmacother 2:23-24
46. Grossmann M, Schmidrams H (2000) An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 38:430-435
47. Lipton RB, Gobel H, Wilks K et al (2002) Efficacy of petasites (an extract from Petasites rhizome) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo-controlled study (Abstract). Neurology 58:A472
48. Montagna P, Cortelli P, Barbiroli B (1994) Magnetic resonance spectroscopy studies in migraine. Cephalalgia 14:184-193
49. 31P NMR spectroscopy alterations in migraine patients. J Neurol Sci 104:182-189
50. Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD (2002) Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22:137-141
51. Sandor P, Clemente D, Coppola L et al (2004) A randomized controlled trial of coenzyme Q10 in migraine prophylaxis (abstract). Neurology 62[Suppl 5]:356-357